Discontinuation Cluster · SSRI
Lexapro (Escitalopram) Onsite Taper
Onsite escitalopram (Lexapro) taper bridged with sub-psychoactive iboga total alkaloid — eliminates brain zaps, dizziness, and emotional rebound.
Generic name
Escitalopram
Drug class
SSRI
Half-life class
intermediate
Plasma half-life
≈ 27–32 hours
Typical dose range
5–20 mg/day
Onsite taper duration
10–18 days onsite
TA bridge
Iboga TA 50–150 mg BID (sub-psychoactive)
Quick Answer
Can I taper off Lexapro (Escitalopram) at MindScape?
Reviewed by Dr. Arellano, M.D. — May 2026
Withdrawal Profile
- Brain zaps (electric-shock paresthesias)
- Dizziness, vertigo, gait instability
- Anxiety rebound and panic surges
- Irritability and emotional lability
- Insomnia and vivid dreaming
Why It's Hard To Taper At Home
- The 5 mg → 2.5 mg → 0 step is the steepest receptor-occupancy drop in the entire taper curve.
- Most patients tapering escitalopram at home reinstate within 2 weeks because the symptoms are misattributed to underlying depression.
- Compounded liquid escitalopram is rarely available outside specialty pharmacies.
MindScape Onsite Protocol
- Baseline cardiac, hepatic, electrolyte, and pharmacogenomic workup.
- Hyperbolic taper using compounded liquid escitalopram: 50% step reductions every 5–7 days.
- Iboga TA bridge 50–150 mg BID through the steepest receptor-occupancy drop.
- Continuous telemetry; symptom-driven adjuncts (ondansetron, hydroxyzine, magnesium).
Day-By-Day Patient Experience
- Days 1–3: workup, magnesium loading, first dose reduction with TA cover.
- Days 4–10: hyperbolic step-downs; TA bridge prevents brain zaps and dizziness peaks.
- Days 11–14: full discontinuation; integration begins.
- Days 15–18: optional ibogaine HCl flood for eligible candidates.
Day-counts and step-cadences are illustrative ranges, not personal medical advice. Individual taper duration is determined onsite by the medical team after baseline workup.
Citations & Reading
- Horowitz MA, Taylor D. (2019). Lancet Psychiatry, 6(6), 538-546.
- Hengartner MP, et al. (2020). Frontiers in Psychiatry, 11, 569.
For the broader iboga-TA evidence base, see the 2026 evidence-base review and the onsite taper cohort methodology page.
Other SSRI taper guides
Zoloft (Sertraline)
Onsite sertraline (Zoloft) taper bridged with sub-psychoactive iboga total alkaloid under continuous cardiac telemetry.
Prozac (Fluoxetine)
Onsite fluoxetine (Prozac) taper using its long-half-life metabolite as a built-in bridge, augmented by full-spectrum iboga TA.
Paxil (Paroxetine)
Onsite paroxetine (Paxil) taper — the SSRI most associated with severe discontinuation syndrome — bridged with full-spectrum iboga TA.